WO2017201624A1 - Composition pour administration transdermique de glutathion - Google Patents

Composition pour administration transdermique de glutathion Download PDF

Info

Publication number
WO2017201624A1
WO2017201624A1 PCT/CA2017/050631 CA2017050631W WO2017201624A1 WO 2017201624 A1 WO2017201624 A1 WO 2017201624A1 CA 2017050631 W CA2017050631 W CA 2017050631W WO 2017201624 A1 WO2017201624 A1 WO 2017201624A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight percent
transdermal formulation
formulation
glutathione
latex
Prior art date
Application number
PCT/CA2017/050631
Other languages
English (en)
Inventor
Rachel Sarah LEVINE
Original Assignee
Levine Rachel Sarah
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Levine Rachel Sarah filed Critical Levine Rachel Sarah
Publication of WO2017201624A1 publication Critical patent/WO2017201624A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present embodiments generally relate to a composition for transdermal delivery of glutathione.
  • Figure 1 depicts a transdermal delivery system according to one or more embodiments.
  • Figure 2 depicts a detail of the latex-free hypoallergenic adhesive patch according to one or more embodiments.
  • Figure 3 depicts Formulation 4 according to one or more embodiments.
  • Figure 4 depicts Formulation 5 according to one or more embodiments.
  • Figure 5 depicts Formulation 6 according to one or more embodiments.
  • FIG. 6 depicts Formulation 7 according to one or more embodiments.
  • Figure 9 depicts Formulation 10 according to one or more embodiments.
  • Figure 10 depicts Formulation 11 according to one or more embodiments.
  • Figure 11 depicts Formulation 12 according to one or more embodiments.
  • Figure 12 depicts Formulation 13 according to one or more embodiments.
  • Figure 13 depicts Formulation 14 according to one or more embodiments.
  • Figure 14 depicts Formulation 15 according to one or more embodiments.
  • Figure 15 depicts Formulation 16 according to one or more embodiments.
  • Figure 16 depicts Formulation 17 according to one or more embodiments.
  • the present embodiments generally relate to a composition for transdermal delivery of glutathione.
  • the present embodiment further relate to a transdermal formulation which can be applied as a latex-free hypoallergenic adhesive patch or transdermal delivery cream using a combination of glutathione, Vitamin D, arnica, glycol, a buffer and a base cream resilient in the presence of a wide range of drugs while increasing permeation of active antioxidant agents, water, isopropyl myristate, polyoxyethylene sorbitan monooleate, isopropyl palmitate, ascorbic acid, and dimethyl sulfoxide.
  • the buffer can be sodium bicarbonate with a pH from 5-8.
  • transdermal formulation For patients unable to take antioxidants and vitamins in more common forms, such as pills and injections, the use of a transdermal formulation can often mean the difference between treatment success or treatment failure.
  • transdermal formulation can be administered as a transdermal delivery cream or in the form of a latex -free hypoallergenic adhesive patch allowing antioxidants and vitamins to successfully penetrate the skin.
  • vitamin D can improve absorption of glutathione.
  • the transdermal formulation can avoid many common side effects of drugs, such as upset stomach, and minimize the effects on other organs.
  • the reduction of side effects is particularly significant in sleep treatment, where the application of the formulation can be localized to an area with relatively low blood-flow. Therefore, higher concentrations at the site of application and lower concentrations of the drug throughout the body enable a patient to restfully stay asleep.
  • a benefit of the embodiments is that the transdermal formulation can help prevent an early onset of aging and cancer in patients, which can cause an accelerated death.
  • the embodiments can help save lives by providing preventive care to patients to avoid life threatening illness.
  • the transdermal formulation can be a hypoallergenic delivery system.
  • the transdermal formulation can use a delivery system that is latex-free.
  • Latex is a toxic material, which can be harmful to the environment and cause some individuals to have a significant allergic reaction, such as irritating itchy rashes and even anaphylactic shock.
  • the embodiments can provide an easy to apply latex -free hypoallergenic adhesive patch that does not require special nursing skills or child proof containers.
  • the package can be easily opened from a vacuum sealed sleeve.
  • the embodiments can provide a drug delivery system, which can prevent individuals from choking on the medication.
  • the invention can be a transdermal formulation in a carrier, such as a cream, a gel or a foam.
  • a carrier such as a cream, a gel or a foam.
  • the transdermal formulation as a cream can be 0.1 weight percent to 5 weight percent glutathione and 0.1 weight percent to 5 weight percent aloe.
  • An example of the transdermal formulation of a gel can be 0.1 weight percent to 5 weight percent glutathione, 0.5 weight percent to 5 weight percent aloe, and 0.5 weight percent to 5 weight percent arnica.
  • An example of the transdermal formulation as a foam can be 0.1 weight percent to 5 weight percent glutathione, 0.5 weight percent to 5 weight percent Vitamin D, and 0.5 weight percent to 3 weight percent aloe.
  • the glutathione can be a powder.
  • the latex-free hypoallergenic adhesive patch can have a first side and a second side.
  • the latex-free hypoallergenic adhesive patch can be from 1 centimeter x 1 centimeter to 3 centimeters x 3 centimeters.
  • the transdermal formulation and a magnesium component can be disposed on the same side of the latex -free hypoallergenic adhesive patch.
  • the type of adhesive used for the latex -free hypoallergenic adhesive patch can be an acrylic adhesive.
  • the latex-free hypoallergenic adhesive patch can be formed from a continuous sheet of a type of closed cell foam, known as polyethylene foam, which can be very thin such as from 0.001 millimeters to 0.2 millimeters in thickness.
  • a layer of adhesive can be disposed on the closed foam in a thickness from 0.001 millimeters to 0.01 millimeters.
  • the adhesive can be an easily removable adhesive that does not cause rashes or otherwise aggravate the patient's skin. Also, the adhesive can be waterproof.
  • the latex -free hypoallergenic adhesive patch can be a reservoir patch with an absorbent pad and foam on the back or a monolithic patch.
  • a therapeutically effective amount of the transdermal formulation can be three different formulations.
  • the first formulation can have 4 weight percent to 10 weight percent glutathione, 0.5 weight percent to 3 weight percent Vitamin D, with no less than 1 unit and no more than 5000 units, 18 weight percent to 20 weight percent glycol, 3 weight percent to 9 weight percent sodium bicarbonate and 47 weight percent to 58 weight percent base cream that is resilient in the presence of a wide range of drugs while increasing permeation of active antioxidant agents.
  • a strip of magnesium glycinate can be attached on the first formulation.
  • the strip of magnesium glycinate can be one continuous strip that extends across the entire formulation.
  • the magnesium glycinate can be installed on the formulation as a series of strips, which can be offset from each other.
  • the strip of the magnesium glycinate can be from 1/4 centimeters to 10 centimeters in length, from 0.25 centimeters to 15 centimeters in width and can cover from 1 percent to 100 percent of the latex-free hypoallergenic adhesive patch.
  • the 1 weight percent to 20 weight percent magnesium glycinate can be added to the transdermal delivery cream and a latex-free hypoallergenic adhesive patch.
  • the embodiments can provide a dosage amount of the formulation either in a transdermal delivery cream or on the latex-free hypoallergenic adhesive patch for delivery to a patient over a unit of time, such as from at least 24 hours to 48 hours.
  • the dosage amount creates in the patient (i) regulation of sleep, (ii) increased energy during awake periods, (iii) improved concentration during awake periods, (iv) reduction of facial wrinkles, and (v) reduction of joint and muscular pain, which can increase by at least 10 percent the ability of skin to retain moisture and totally absorb the glutathione without requiring an injection or oral supplementation of the glutathione.
  • Formulation 1 - Example 1 [00052] Bill, a 45 year old male, weighing 220 pounds and having Type 1 diabetes fasted from Midnight to 8:00 am prior to application of the transdermal delivery system. Under a strong light at approximately 8:00 am, a baseline of wrinkles was visually computed as 22 wrinkles per side of his face for a total of 44 wrinkles.
  • the transdermal delivery system with formulation 1 can use the following weight percents: 10 weight percent glutathione, 2 weight percent Vitamin D (1000 units), 19 weight percent glycol, 3.5 weight percent sodium bicarbonate, and 55.5 weight percent base cream was used.
  • formulation 1 can include 1 weight percent to 5 weight percent arnica. [00055] Formulation 1 on the latex-free hypoallergenic adhesive patch was applied to Bill's right forearm between the wrist and elbow for 46 hours.
  • the latex-free hypoallergenic adhesive patch was removed at approximately 11 :00 am and the wrinkle count was found to be reduced to about 10 percent, which is a total 39 wrinkles +/-5 percent.
  • the transdermal delivery cream of formulation 1 can use the following weight percent: 5 weight percent glutathione, 2 weight percent Vitamin D (1000 units), 18 weight percent glycol, 3.5 weight percent sodium bicarbonate, and 46.5 weight percent base cream was used.
  • formulation 1 can include 1 weight percent to 5 weight percent arnica and aloe.
  • the transdermal delivery cream was applied at 6:00 am each morning and 10:00 pm each evening. [00062] The transdermal delivery cream application was halted after 48 hours at approximately 10:00 pm. On the following morning at 6:30 am, the wrinkle count was found to have been reduced by 7 percent around the between the eyebrow and upper cheeks to a total of 9 wrinkles on each side and reduction of depths of the wrinkles by 5 percent.
  • Fred a 75 year old man weighing 175 pounds, has a significant amount of scrofulous eczema on the upper part of his face, ears and hairline.
  • Fred has a history of excessive drinking and smoking for at least 30 years.
  • Fred has suffered persistent flaking and itching from the eczema for many years.
  • Fred fasted from 11 :00 pm until 7:00 am the following morning, with only an intake of 1 glass of water in the middle of the night prior to the transdermal delivery system. Under a strong light, it was noted that there were red patches, which had raised bumps on the upper cheeks below the eyes, red flaking patches along both sides of the hairline and redness on upper parts of his ears.
  • the latex-free hypoallergenic adhesive patch of formulation 1 can use the following weight percents: 10 weight percent glutathione, 3 weight percent Vitamin D (2000 units), 20 weight percent glycol, 3.5 weight percent sodium bicarbonate, and 61.5 weight percent base cream was used. [00066] In embodiments, formulation 1 can include 1 weight percent to 5 weight percent arnica.
  • the latex-free hypoallergenic adhesive patch was applied at 7: 15 am to the under part of his upper left arm.
  • the latex-free hypoallergenic adhesive patch was removed after 48 hours at approximately 7:00 am and the reduction of redness subsided by 30 percent.
  • the scrofulous flaking was reduced by 17 percent especially in the highly affected areas along the hairline and the upper cheeks.
  • the itching was reduced by 20 percent giving significant relief during the 48 hours of wearing the transdermal delivery system.
  • formulation 1 does not only affect wrinkles, but can reduce the time of healing for burns and prevent oxidative stress.
  • Oxidative stress is an imbalance between the production of free radicals and the ability of the body to counteract or detoxify their harmful effects through neutralization by antioxidants.
  • formulation 1 can assist in eczema treatment.
  • formulation 1 can be used for skin lightening.
  • Formulation 2 :
  • the second formulation can have 4 weight percent to 10 weight percent glutathione, 75 weight percent to 85 weight percent water, 3 weight percent to 9 weight percent sodium bicarbonate, and 0.1 weight percent to 1 weight percent propylene glycol.
  • formulation 2 can include 1 weight percent to 5 weight percent arnica.
  • Sally is a 60 year old woman who has had difficulty falling sleeping for two years since the death of her husband. Consistently, Sally cannot fall asleep before 12:00 am even though she retires at 10:00 pm. In turn, Sally's energy dips at 2:00 pm each afternoon, approximately two hours after she eats lunch.
  • the latex-free hypoallergenic adhesive patch of formulation 2 can use the following weight percents: 10 weight percent glutathione, 83 weight percent water, 3.5 weight percent sodium bicarbonate, and 1.5 weight percent propylene glycol.
  • formulation 2 can include 1 weight percent to 5 weight percent arnica.
  • the latex-free hypoallergenic adhesive patch was administered at 6:30 am, and she wore the latex-free hypoallergenic adhesive patch for 45 hours. Sally reported that her energy at 2:00 pm increased by 12 percent the first day and about 20 percent on the second day. Her sleep improved significantly, and she was able to fall asleep one-half hour after retiring to bed at 10:00 pm. Therefore, Sally had a significant improvement of 90 percent.
  • the transdermal delivery cream of formulation 2 can use the following weight percents: 9 weight percent glutathione, 84.5 weight percent water, 3.5 weight percent sodium bicarbonate, and 1.5 weight percent propylene glycol.
  • formulation 2 can include 1 weight percent to 5 weight percent arnica.
  • the transdermal delivery cream was administered at 9:00 pm and again at 7:30 am for 48 hours on the temples of her face as well on her chest. Jessica reported that she did wake at 5:00 am both mornings but was able to fall back asleep fairly quickly and woke at 6:30 am feeling more refreshed. Her energy at 4:00 pm was increased by 30 percent both days and her 9:00 pm burst of energy subsided by 40 percent allowing her to fall asleep at 10:30 pm. Therefore, providing Jessica with almost a solid eight hours of sleep for 48 hours.
  • the latex-free hypoallergenic adhesive patch of formulation 2 can use the following weight percents: 10 weight percent glutathione, 84.5 weight percent water, 4 weight percent sodium bicarbonate, and 1.5 weight percent propylene glycol.
  • the latex-free hypoallergenic adhesive patch was administered at 9:30 am, and he wore the latex-free hypoallergenic adhesive patch for 48 hours. Malcolm reported that he woke up once the first night at 2:00 am, but fell back asleep almost immediately and slept through the night completely the second night.
  • formulation 2 can additionally provide quantitative benefits for the regulation of sleep and increased energy during awake periods.
  • formulation 2 can prevent leaky-gut syndrome, which can be a result of celiac disease.
  • Formulation 3 Formulation 3 :
  • the third formulation can have 4 weight percent to 10 weight percent glutathione, 47 weight percent to 56 weight percent water, 3 weight percent to 9 weight percent sodium bicarbonate 1, weight percent to 5 weight percent polyoxyethylene sorbitan monooleate, 2 weight percent to 5 weight percent ascorbic acid, and 4 weight percent to 10 weight percent dimethyl sulfoxide.
  • formulation 3 can include 1 weight percent to 5 weight percent arnica.
  • formulation 3 can provide improved concentration during awake periods and reduction of joint and muscular pain and increase the ability of skin to retain moisture and totally absorb the glutathione without requiring injections or oral supplementation by at least 10 percent while the formulation is on the skin either as a transdermal delivery cream or a latex -free hypoallergenic adhesive patch.
  • the effects of the third formulation can continue for at least 24 hours while the skin is still absorbing the formulation and continues to affect the body for at least 3 days and up to 6 days depending upon the age of the individual.
  • the latex-free hypoallergenic adhesive patch of formulation 3 can use the following weight percents: 6 weight percent glutathione, 3.5 weight percent sodium bicarbonate, 56.5 weight percent water, 3 weight percent polyoyethylene sorbitan monooleate, 3 weight percent ascorbic acid, 6 weight percent dimethyl sulfoxide, and 3 weight percent arnica
  • the transdermal delivery cream of formulation 3 can use the following weight percents: 5 weight percent glutathione, 3.5 weight percent sodium bicarbonate, 56.5 weight percent water, 2 weight percent polyoyethylene sorbitan monooleate, 2 weight percent ascorbic acid, 4 weight percent dimethyl sulfoxide, 5 weight percent arnica, and 3 weight percent aloe.
  • the transdermal delivery cream was applied to David's affected legs and upper shoulders for a total of 48 hours. He applied the transdermal delivery cream after training at 11 :00 am each day and before going to bed each night at 11 :00 pm.
  • the latex-free hypoallergenic adhesive patch of formulation 3 can use the following weight percents: 10 weight percent glutathione, 3.5 weight percent sodium bicarbonate, 61.5 weight percent water, 5 weight percent polyoyethylene sorbitan monooleate, 5 weight percent ascorbic acid, 5 weight percent dimethyl sulfoxide, and 4 weight percent arnica. [000110] The latex-free hypoallergenic adhesive patch was applied to Michael at 10:00 pm for
  • Figure 1 depicts a transdermal delivery system according to one or more embodiments.
  • the transdermal delivery system 10 can be applied to a user 11. While the transdermal delivery system 10 is shown attached to the user's forearm, it is understood that the transdermal delivery system can be attached to other areas of the user's body.
  • the transdermal delivery system 10 can be in the form of a latex -free hypoallergenic adhesive patch 12, which can have a layer of the formulation 14, such as in the center of the latex-free hypoallergenic adhesive patch 12.
  • Figure 2 depicts a detail of the latex-free hypoallergenic adhesive patch according to one or more embodiments.
  • the latex-free hypoallergenic adhesive patch 12 can have a backing layer 19, which can be a thin film polymer that can be waterproof and hypoallergenic. [000117] In embodiments, portions of an adhesive 16a and 16b can be positioned on the backing layer 19, such as on opposing edges but on the same side as the layer of the formulation 14.
  • a plurality of offset strips of magnesium glycinate 20a, 20b, and 20c can be disposed on the layer of the formulation 14.
  • Figure 3 depicts Formulation 4.
  • transdermal Formulation 4 greatly increases the mental focus in both men and women of all ages within a time span of one hour. It will continue to help achieve clarity and focus for up to 48 hours at a time.
  • Figure 4 depicts Formulation 5.
  • Formulation 5 can be applied as a transdermal cream or a gel to the skin for anti-aging as it actively starts to repair the elasticity to the face by 10 percent in the first 24 hours followed by a 10 percent reduction each day following with the reduction of wrinkles around the eyes.
  • Figure 5 depicts Formulation 6.
  • Formulation 6 applied a cream is excellent for bruising, muscle pain and acute injuries.
  • Formulation 6 will reduce inflammation within 20 minutes of the application and pain will reduce within 20 minutes of application leading to a 60 percent reduction in discoloration of the bruise within 24 hours.
  • Figure 6 depicts Formulation 7.
  • Formulation 7 applied as a cream or a gel aids in constipation and the reversal of issues pertaining to the gut; such as difficulty with stool, hemorrhoids and acid-reflux. Rectal bleeding should reverse itself within 24-48 hours. Acid-reflux will reduce within two hours of the application and should repair itself over the course of two weeks by 75 percent. Constipation will reverse within 12 hours.
  • Formulation 8 [000129] Figure 7 depict Formulation 8. Within 24 hours of daily and nightly application of the cream to elderly individuals, Formulation 8 will help individuals fall asleep within 30 minutes and will help individuals stay asleep throughout the night. The moisture should be 30 percent better within first 24 hours of using the topical cream which goes into the blood stream similar to the patch. Wrinkles will subside by 15 percent within the first 48 hours of use.
  • Figure 8 depicts Formulation 9.
  • Formulation 9 as a liposomal cream works for the elderly and youth who injure themselves. Once the application of the cream is applied, reduction of pain by 35 percent will occur within 2 hours of use. Inflammation will subside by 50 percent in 24 hour use. Formulation 9 enters the blood stream on application and will accelerate the healing process by clearing up the bruising within 48 hours.
  • Figure 9 depicts Formulation 10.
  • Formulation 10 is for both men and women who struggle with insomnia. Once the transdermal patch is applied, people will fall asleep more easily within 20 minutes of application and will sleep continuously sleep for a consecutive five hours without interruption.
  • Figure 10 depicts Formulation 11. Once the transdermal patch is applied, Formulation
  • Formulation 11 increases energy and focus the following day. Reduction of puffiness in the face from stimulants is reduced by 30 percent the following day and abdominal inflammation is reduced by 20 percent the following day after consuming stimulants.
  • Figure 11 depicts Formulation 12.
  • Formulation 12 aids in the reduction of chronic headaches by 40 percent after applying a transdermal patch or gel. Reduction of migraine pain is reduced within one hour by 25 percent and headache pain by 70 percent within one hour of application. It reduces recurring migraine pain from four hours to two hours then to 20 minutes.
  • Figure 12 depicts Formulation 13.
  • Formulation 13 can help with those with neurological issues such as Parkinson's. Many studies have shown that those with neurological issues have virtually no glutathione and greatly lack Vitamin D in the body.
  • Mary is 62 and weighs 125 pounds before the application of the transdermal patch, her gait was heavily staggered, after wearing the patch, her gait reversed and it allowed her to walk comfortably without a walker within the time span of 30 minutes.
  • Jack who is 74 with Parkinson's weight 180 pounds, after wearing the patch his gait reversed by 50 percent within one hour. Although he still needed a walker, he walked more comfortably.
  • Figure 13 depicts Formulation 14.
  • Phase A In a suitable tank or vessel, add 54.55 weight percent of purified water. Start heating to 80°C. Into a separate suitable container, disperse xanthan gum in glycerine. Then, add it into water while mixing at medium speed. Continue heating to 80°C.
  • Phase B Into another mixing vessel, mix 3 weight percent of isopropyle myristate, 6 weight percent cetearyl oliviate, 3 weight percent caprylic/capric triglycerides, 3.5 weight percent stearyl alcohol, 3 weight percent cetyl alcohol, 2 weight percent helianthus annuus (sunflower) seed oil, and 5 weight percent soy lecithin of Phase B in order. After all ingredients are added, turn the propeller on at low to medium speed. Continue mixing and heating to 75 - 80°C.
  • phase A water phase
  • Phase C Prepare premix of 6 weight percent of purified water and 5 weight percent of glutathione. At 50°C, add phase C premix into the batch, part by part, while mixing at 2500-3000 rpm speed. Mix for 10 minutes.
  • Phase D At 50°C, add 0.5 weight percent essential oil into the batch slowly while mixing at medium speed. Mix for 10 minutes.
  • Phase E Prepare premix of 3 weight percent water and 1.5 weight percent geogard ultra and add it into the batch at 50°C. Then, add 0.3 weight percent glyceryl caprylate into the batch while mixing at 2500-3000 rpm speed. Mix for 10 minutes.
  • Phase A In a suitable tank or vessel, add 49.550 weight percent of purified water.
  • Phase B Into another mixing vessel, mix 3 weight percent of isopropyle myristate blended, 6 weight percent cetearyl oliviate, 3.5 weight percent caprylic/capric triglycerides, 3.5 weight percent stearyl alcohol, 3 weight percent cetyl alcohol, 5 weight percent of arnica montana oil, 2 weight percent helianthus annuus seed oil, and 5 weight percent soy lecithin in order. After all ingredients are added, turn propeller on at low to medium speed. Continue mixing and heating to 75 - 80°C.
  • phase A water phase
  • Phase C Prepare premix of 6 weight percent of purified water and 5 weight percent of glutathione. At 50°C, add phase C premix into the batch slowly, part by part while mixing at medium speed. Mix for 10 minutes.
  • Phase D At 50°C, add 0.5 weight percent essential oil into the batch, part by part, while mixing at 2500-3000 rpm speed. Mix for 10 minutes.
  • Phase E Prepare premix of 3 weight percent water and 1.5 weight percent geogard ultra and add it into the batch at 50°C. Then, add 0.3 weight percent glyceryl caprylate into the batch while mixing at 2500-3000 rpm speed. Mix for 10 minutes.
  • Formulation 15 as a liposomal cream works for post-surgical scarring. Once the application of the cream is applied, the redness and permeated presentation reduces by 15 percent within the first 24 hours. Over the course of applied cream for one month, the scaring on the affected part reduces by 80 percent allowing the individual to have a returned state of healthier skin presentation.
  • Phase A In a suitable tank or vessel, add 49.550 weight percent of purified water.
  • Phase B Into another mixing vessel, mix 3.5 weight percent of isopropyle myristate,
  • phase A water phase
  • Phase C Prepare premix of 6 weight percent of purified water and 7 weight percent of glutathione. At 50°C, add phase C premix into the batch slowly, part by part while mixing at medium speed. Mix for 10 minutes.
  • Phase D At 50°C, add 0.5 weight percent essential oil into the batch, part by part, while mixing at 2500-3000 rpm speed. Mix for 10 minutes.
  • Phase E Prepare premix of 3 weight percent water and 1.5 weight percent geogard ultra and add it into the batch at 50°C. Then, add 0.3 weight percent glyceryl caprylate into the batch while mixing at 2500-3000 rpm speed. Mix for 10 minutes.
  • Formulation 16 as a liposomal cream works for the elderly who are experiencing insomnia. Once the application of the cream is applied, an hour before bed, the ability to fall asleep will increase 35 percent will occur within 2 hours of use. The ability to sleep through the night will increase by 50 percent in first night of an eight hour sleep. This formula enters the blood stream on application.
  • Figure 16 depicts Formulation 17.
  • Phase A In a suitable tank or vessel, add 52.550 weight percent of purified water.
  • Phase B Into another mixing vessel, mix has 3 weight percent of isopropyle myristate, 6 weight percent cetearyl oliviate, 3 weight percent caprylic/capric triglycerides, 3.5 weight percent stearyl alcohol, 3.2 weight percent cetyl alcohol, 3.80 weight percent helianthus annuus seed oil, and 4 weight percent soy lecithin of Phase B in order. After all ingredients are added, turn the propeller on at low to medium speed. Continue mixing and heating to 75 - 80°C.
  • phase A water phase
  • Phase C Prepare premix of 6 weight percent of purified water and 6 weight percent of glutathione. At 50°C, add phase C premix into the batch, part by part, while mixing at 2500-3000 rpm speed. Mix for 10 minutes.
  • Phase D At 50°C, add 0.5 weight percent essential oil into the batch slowly while mixing at medium speed. Mix for 10 minutes.
  • Phase E Prepare premix of 3 weight percent water and 1.5 weight percent geogard ultra and add it into the batch at 50°C. Then, add 0.3 weight percent glyceryl caprylate into the batch while mixing at 2500-3000 rpm speed. Mix for 10 minutes.
  • Formula 17 as a liposomal cream works for teenagers who are experiencing severe acne. Once the application of the cream is applied on the face, a reduction of cystic pimples starts to decrease by 35 percent within the first 48 hours of use while the reduction of white heads start to reduce by 45 percent. Over the course of two weeks, there is a reduction of acne by 75 percent of the total face of the teenager and there is a reduction of recurring cystic pimples. While these embodiments have been described with emphasis on the embodiments, it should be understood that within the scope of the appended claims, the embodiments might be practiced other than as specifically described herein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une formulation transdermique qui peut être appliquée sur la peau sous la forme d'un timbre adhésif hypoallergénique sans latex ou d'une crème d'administration transdermique utilisant une combinaison de glutathion, de vitamine D, de glycol, de bicarbonate de sodium et de crème de base élastique en présence d'une large gamme de médicaments tout en augmentant la perméation d'agents antioxydants actifs, d'eau, de myristate d'isopropyle, de monooléate de sorbitane polyoxyéthylénique, de palmitate d'isopropyle, d'acide ascorbique et de diméthylsulfoxyde. La quantité de dose peut produire chez le patient (i) la régulation du sommeil, (ii) une énergie accrue pendant les périodes d'éveil, (iii) une concentration améliorée pendant les périodes d'éveil, (iv) une réduction des rides faciales, et (v) une réduction des douleurs articulaires et musculaires avec des augmentations d'au moins 10 pour cent de la capacité de la peau à retenir l'humidité et absorber totalement le glutathion sans nécessiter une injection ou une supplémentation orale du glutathion.
PCT/CA2017/050631 2016-05-25 2017-05-24 Composition pour administration transdermique de glutathion WO2017201624A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662341562P 2016-05-25 2016-05-25
US62/341,562 2016-05-25

Publications (1)

Publication Number Publication Date
WO2017201624A1 true WO2017201624A1 (fr) 2017-11-30

Family

ID=60411013

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2017/050631 WO2017201624A1 (fr) 2016-05-25 2017-05-24 Composition pour administration transdermique de glutathion

Country Status (1)

Country Link
WO (1) WO2017201624A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10548830B2 (en) * 2017-05-24 2020-02-04 Rachel Sarah Levine Composition for transdermal delivery of glutathione

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101401783A (zh) * 2007-09-16 2009-04-08 杨喜鸿 含有艾拉莫德的透皮吸收剂及其制备方法和它的药物应用
CN106726771A (zh) * 2016-12-28 2017-05-31 安徽檀鑫科技有限公司 一种补水抗皱眼霜及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101401783A (zh) * 2007-09-16 2009-04-08 杨喜鸿 含有艾拉莫德的透皮吸收剂及其制备方法和它的药物应用
CN106726771A (zh) * 2016-12-28 2017-05-31 安徽檀鑫科技有限公司 一种补水抗皱眼霜及其制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10548830B2 (en) * 2017-05-24 2020-02-04 Rachel Sarah Levine Composition for transdermal delivery of glutathione

Similar Documents

Publication Publication Date Title
JP4352114B2 (ja) 有益な効果を奏するアルギニンの投薬
US5976547A (en) Analgesic and antiphlogistic compositions and therapeutic wrap for topical delivery
AU2008266971B2 (en) Topical composition for treating pain
JP2002515401A5 (fr)
KR20060019540A (ko) 경피 투여용 국소 조성물
GB2177919A (en) Synergistic compositions for treating skin/mucosa
US20200171119A1 (en) Composition for transdermal delivery of glutathione
US10548830B2 (en) Composition for transdermal delivery of glutathione
BR102019013368A2 (pt) composições e métodos para tratamento de condições da pele usando luz e cloridrato de glicosamina
US10314779B2 (en) Composition for transdermal delivery of glutathione
WO2017201624A1 (fr) Composition pour administration transdermique de glutathion
WO1994005272A1 (fr) Compositions destinees au traitement de l'epiderme, contenant du dimethylsulfone et du dimethylsulfoxyde
US6399108B1 (en) Compositions and methods for the treatment of skin disorders
JP5998399B1 (ja) 痒み防止剤
EP1752132A2 (fr) Compositions cosmétiques pour la peau
Heimbach et al. Minor burns: guidelines for successful outpatient management
Lewis The effect of β‐carotene on serum vitamin A levels in erythropoietic protoporphyria
US20160101141A1 (en) Topical Treatment of Sports Related Injuries
CN101185622B (zh) 控油防黑白嫩霜
CA2620242A1 (fr) Cicatrisant des contusions a lenifiant topique
EP2712613A1 (fr) Vitamine K1 et ses utilisations
KR20120102214A (ko) 한방복합 생약 소염 진통 외용제
TWI325324B (fr)
CANNON Treatment of lupus erythematosus disseminatus by internal administration of iodine
Allen et al. Delayed use of antivenin in black widow spider (Latrodectus mactans) envenomation

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17801874

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17801874

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 17.06.2019)

122 Ep: pct application non-entry in european phase

Ref document number: 17801874

Country of ref document: EP

Kind code of ref document: A1